Barclays Expands Coverage To 7 New Biotech Stocks

Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]